Leerink Partnrs Predicts argenx’s Q2 Earnings (NASDAQ:ARGX)

argenx SE (NASDAQ:ARGX) – Investment analysts at Leerink Partnrs reduced their Q2 2025 earnings estimates for argenx in a note issued to investors on Friday, May 9th. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings of $2.19 per share for the quarter, down from their prior forecast of $2.40. The consensus estimate for argenx’s current full-year earnings is $3.13 per share. Leerink Partnrs also issued estimates for argenx’s Q3 2025 earnings at $2.60 EPS and Q4 2025 earnings at $2.93 EPS.

argenx (NASDAQ:ARGX) last released its quarterly earnings results on Thursday, May 8th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.32 by $0.26. The firm had revenue of $1.35 billion for the quarter, compared to analyst estimates of $748.34 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%.

A number of other brokerages have also issued reports on ARGX. Oppenheimer upped their target price on shares of argenx from $704.00 to $708.00 and gave the stock an “outperform” rating in a research report on Friday. JMP Securities upped their target price on shares of argenx from $606.00 to $696.00 and gave the stock a “market outperform” rating in a research report on Tuesday, January 14th. Guggenheim reduced their target price on shares of argenx from $1,100.00 to $1,065.00 and set a “buy” rating on the stock in a research report on Friday. Sanford C. Bernstein upgraded shares of argenx from a “market perform” rating to an “outperform” rating in a research report on Monday, March 17th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of argenx from a “sell” rating to a “hold” rating in a research report on Wednesday, March 12th. Three analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $697.94.

argenx Stock Down 3.4%

NASDAQ:ARGX opened at $549.65 on Monday. The firm has a market cap of $33.56 billion, a PE ratio of -624.60 and a beta of 0.57. argenx has a 12 month low of $352.77 and a 12 month high of $678.21. The company’s 50-day moving average price is $596.27 and its two-hundred day moving average price is $613.81.

Institutional Investors Weigh In On argenx

Several large investors have recently bought and sold shares of ARGX. FMR LLC increased its stake in argenx by 17.2% in the fourth quarter. FMR LLC now owns 5,618,222 shares of the company’s stock valued at $3,455,207,000 after purchasing an additional 824,750 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in argenx in the fourth quarter valued at approximately $91,013,000. Allspring Global Investments Holdings LLC increased its stake in argenx by 38,152.3% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 144,211 shares of the company’s stock valued at $89,391,000 after purchasing an additional 143,834 shares in the last quarter. GAMMA Investing LLC increased its stake in argenx by 53,684.9% in the first quarter. GAMMA Investing LLC now owns 135,538 shares of the company’s stock valued at $802,200,000 after purchasing an additional 135,286 shares in the last quarter. Finally, Marshall Wace LLP increased its stake in argenx by 184.7% in the fourth quarter. Marshall Wace LLP now owns 191,553 shares of the company’s stock valued at $117,805,000 after purchasing an additional 124,271 shares in the last quarter. Institutional investors own 60.32% of the company’s stock.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.